Fujifilm of Japan is about to boost production of a drug to treat Ebola fever

Fujifilm of Japan is about to boost production of a drug to treat Ebola fever. Wall Street Journal states that product in an equivalent of 20 thousand full course treatments as well as 300 thousand more worth of API will be produced. The aniviral drug Avigan…

Read more

A leading Geman generics manufacturer Stada that it is in-licensing a biosimilar of Forteo

A leading Geman generics manufacturer Stada announced on October 13, 2014 that it is in-licensing a biosimilar of Forteo (teriparatide) from Richter-Helm BioTec. It will launch the product in Europe in 2019 after the patent on Eli Lilly’s original Forteo expires in December 2018. Teriparatide is a recombinant form of a human parathyroid…

Read more

World pharmaceutical market may reach 1 trillion dollars this year

Thomson Reuters forecasts world pharma market to reach 1 trillion dollars this year.

Read more

Himira’s biosimilar successfully passes clinical trials

AbbVie’s Humira is the world’s top-selling drug with this year’s second quarter revenue of $3.29 bln according to IMS Health.

Read more

European generics industry is undergoing a serious change

European generics manufacturers are switching to biosimilars. Two thirds of drugs losing patent protection in 2014-2020 are biologics or specialty products.

Read more

BIOCAD is developing a new drug for melanoma treatment

At this time BIOCAD is studying several molecules. The most successful candidate will become a new product in 2018-2019.

Candidate molecules are monoclonal antibodies to PD-1 antigen that stimulate patient immune system to destroy cancer cell. BIOCAD is planning to launch 1-2 new generation drugs every year starting in…

Read more

245 companies worldwide are developing 700 biosimilars

The market is biologics may exceed 250 bln USD by 2020. Biosimilars, copies of biologics, are becoming more popular. According to Reuters 245 companies worldwide are currently developing 700 biosimilars.

Biggest players are Teva, Sandoz, Pfizer, and Amgen. Biosimilars popularity can be explained by their profitability:…

Read more

Biologics with a total of $67 bln in global sales will lose patent protection by 2020

Twelve biologics with total global sales of $67 bln will meet generics competition by 2020.

Read more